Q. Le - Academia.edu (original) (raw)

Papers by Q. Le

Research paper thumbnail of Monte Carlo Dose Calculations for IMRT Head-and-Neck Patients With Dental Fillings Using the Phase Space Files for LINAC

International Journal of Radiation Oncology*Biology*Physics, 2012

Research paper thumbnail of Increasing Use of Technology With Palliative Radiation Therapy

International Journal of Radiation Oncology*Biology*Physics, 2012

Research paper thumbnail of Low-Dose Radiation Therapy (2 Gy x 2) in the Treatment of Non-Hodgkin Lymphoma of the Ocular Adnexa

International Journal of Radiation Oncology*Biology*Physics, 2013

Research paper thumbnail of Metabolic Tumor Volume Predicts for Recurrence and Death in Head and Neck Cancer

International Journal of Radiation Oncology*Biology*Physics, 2008

To evaluate the prognostic value of metabolic tumor volume measured on 18F-fluorodeoxyglucose pos... more To evaluate the prognostic value of metabolic tumor volume measured on 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) imaging and other clinical factors in patients treated for locally advanced head-and-neck cancer (HNC) at a single institution. Between March 2003 and August 2007, 85 patients received positron emission tomography (PET)/computed tomography-guided chemoradiotherapy for HNC. Metabolically active tumor regions were delineated on pretreatment PET scans semiautomatically using custom software. We evaluated the relationship of (18)F-fluorodeoxyglucose-PET maximum standardized uptake value (SUV) and total metabolic tumor volume (MTV) with disease-free survival (DFS) and overall survival (OS). Mean follow-up for surviving patients was 20.4 months. The estimated 2-year locoregional control, DFS, and OS for the group were 88.0%, 69.5%, and 78.4%, respectively. The median time to first failure was 9.8 months among the 16 patients with relapse. An increase in MTV of 17.4 mL (difference between the 75th and 25th percentiles) was significantly associated with an increased hazard of first event (recurrence or death) (1.9-fold, p < 0.001), even after controlling for Karnofsky performance status (KPS) (1.8-fold, p = 0.001), and of death (2.1-fold, p < 0.001). We did not find a significant relationship of maximum SUV, stage, or other clinical factors with DFS or OS. Metabolic tumor volume is an adverse prognostic factor for disease recurrence and death in HNC. MTV retained significance after controlling for KPS, the only other significant adverse prognostic factor found in this cohort. MTV is a direct measure of tumor burden and is a potentially valuable tool for risk stratification and guiding treatment in future studies.

Research paper thumbnail of 1097

International Journal of Radiation Oncology*Biology*Physics, 2006

Research paper thumbnail of Female and minority students benefit from use of multimedia case studies

Research paper thumbnail of Monte Carlo Dose Calculations for IMRT Head-and-Neck Patients With Dental Fillings Using the Phase Space Files for LINAC

International Journal of Radiation Oncology*Biology*Physics, 2012

Research paper thumbnail of Increasing Use of Technology With Palliative Radiation Therapy

International Journal of Radiation Oncology*Biology*Physics, 2012

Research paper thumbnail of Low-Dose Radiation Therapy (2 Gy x 2) in the Treatment of Non-Hodgkin Lymphoma of the Ocular Adnexa

International Journal of Radiation Oncology*Biology*Physics, 2013

Research paper thumbnail of Metabolic Tumor Volume Predicts for Recurrence and Death in Head and Neck Cancer

International Journal of Radiation Oncology*Biology*Physics, 2008

To evaluate the prognostic value of metabolic tumor volume measured on 18F-fluorodeoxyglucose pos... more To evaluate the prognostic value of metabolic tumor volume measured on 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) imaging and other clinical factors in patients treated for locally advanced head-and-neck cancer (HNC) at a single institution. Between March 2003 and August 2007, 85 patients received positron emission tomography (PET)/computed tomography-guided chemoradiotherapy for HNC. Metabolically active tumor regions were delineated on pretreatment PET scans semiautomatically using custom software. We evaluated the relationship of (18)F-fluorodeoxyglucose-PET maximum standardized uptake value (SUV) and total metabolic tumor volume (MTV) with disease-free survival (DFS) and overall survival (OS). Mean follow-up for surviving patients was 20.4 months. The estimated 2-year locoregional control, DFS, and OS for the group were 88.0%, 69.5%, and 78.4%, respectively. The median time to first failure was 9.8 months among the 16 patients with relapse. An increase in MTV of 17.4 mL (difference between the 75th and 25th percentiles) was significantly associated with an increased hazard of first event (recurrence or death) (1.9-fold, p < 0.001), even after controlling for Karnofsky performance status (KPS) (1.8-fold, p = 0.001), and of death (2.1-fold, p < 0.001). We did not find a significant relationship of maximum SUV, stage, or other clinical factors with DFS or OS. Metabolic tumor volume is an adverse prognostic factor for disease recurrence and death in HNC. MTV retained significance after controlling for KPS, the only other significant adverse prognostic factor found in this cohort. MTV is a direct measure of tumor burden and is a potentially valuable tool for risk stratification and guiding treatment in future studies.

Research paper thumbnail of 1097

International Journal of Radiation Oncology*Biology*Physics, 2006

Research paper thumbnail of Female and minority students benefit from use of multimedia case studies